KHẢO SÁT NỒNG ĐỘ APOB, APOA-1 VÀ CHỈ SỐ APOB/APOA-1 Ở BỆNH NHÂN BỆNH THẬN MẠN CHƯA LỌC MÁU

Abstract

Background: Dyslipidemia is a major cardiovascular risk factor in chronic kidney disease (CKD). ApoB, ApoA-1, and the ApoB/ApoA-1 ratio are considered better indicators of atherosclerotic risk than traditional lipids; however, their variation across CKD stages remains controversial. Objectives: To determine the concentrations of ApoB, ApoA-1, and the ApoB/ApoA1 ratio, and to compare their differences across CKD stages. Materials and methods:  A crosssectional study was conducted on 70 patients with CKD stages 2-4 in Can Tho from 2025 to 2026. Serum ApoB and ApoA-1 levels were quantified, and differences were analyzed using ANOVA. Results: The mean age was 62.8 ± 15.4 years. The mean concentrations of ApoB and ApoA-1 were 95.5 ± 34.9 mg/dL and 147.0 ± 29.9 mg/dL, respectively. The mean ApoB/ApoA-1 ratio was 0.67 ± 0.24ApoB levels in female patients were significantly higher than in males (p<0.05). There were no statistically significant differences in ApoB, ApoA-1 concentrations, and the ApoB/ApoA-1 ratio across CKD stages 2 to 4 (p>0.05). Conclusion: Apolipoprotein concentrations and the ApoB/ApoA-1 ratio did not show significant variations across CKD stages 2 to 4. However, the mean ApoB/ApoA-1 ratio of 0.67 suggests a shift in lipid balance towards atherogenesis, with ApoB accumulation being particularly more pronounced in female patients.